24 Apr 2020 11:26
Concepta PLC
("Concepta" or the "Company")
Result of General Meeting & Completion of Fundraise
Concepta PLC (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus®"), the UK's most accurate home-use fertility tracking and pregnancy testing system, announces that all the Resolutions set out in the Circular dated 8 April 2020 (the "Circular"), were duly passed at the General Meeting of the Company held earlier today.
The Resolutions include those necessary to implement the Fundraise to raise a total of £1.9 million (before expenses). Details of voting are provided below:
Resolution | For | Against |
Resolution 1 | 73,379,504 | 2,068,271 |
Resolution 2 | 73,382,504 | 2,068,271 |
Resolution 3 | 73,379,504 | 2,068,271 |
Resolution 4 | 73,379,504 | 2,071,271 |
Resolution 5 | 72,706,624 | 2,744,151 |
Admission to AIM
Following the announcement made on 8 April 2020 and the passing of the Resolutions at the General Meeting today, the 224,875,000 Placing Shares and Subscription Shares have been allotted and will be admitted to trading on AIM at 8.00 a.m. on 27 April 2020. These shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
Directors' Shareholdings
Mercia is a substantial shareholder in the Company, and is connected to Director Peter Dines. Penny McCormick, Maddy Kennedy, Lyn Rees and Adam Reynolds are Directors of the Company.
The holdings of each of Mercia GP, Mercia EIS, Penny McCormick, Maddy Kennedy, Lyn Rees and Adam Reynolds following Admission are shown below:
Name | Amount subscribed | Existing shares in the Company | Number of Subscription Shares | No of Ordinary Shares held post Admission | % of Ordinary Share Capital held post Admission |
Mercia † | £599,000 | 72,036,395 | 74,875,000 | 146,911,395 | 29.99% |
Penny McCormick | £10,000 | - | 1,250,000 | 1,250,000 | 0.26% |
Maddy Kennedy | *£10,000 | - | 1,250,000 | 1,250,000 | 0.26% |
Lyn Rees | £12,500 | - | 1,562,500 | 1,562,500 | 0.32% |
Adam Reynolds | £50,000 | 1,834,722 | 6,250,000 | 8,084,722 | 1.65% |
*Half of the subscription by Maddy Kennedy hasbeen made by her husband.
† Mercia's investment is split between Mercia GP (£99,000) and Mercia EIS (£500,000). Mercia's existing and post-Admission holding includes 12,699,967 shares held by Enterprise Ventures (General Partner FY Seedcorn) Limited as general partner of Finance Yorkshire Seedcorn LP.
Total Voting Rights
Following Admission, the Company will have a total of 489,821,675 Ordinary Shares in issue with each Ordinary Share carrying the right of one vote. The above figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Definitions used in this announcement are the same as those used in the Circular.
Concepta plc | www.conceptaplc.com |
Penny McCormick, Chief Executive Officer | via Walbrook PR |
Maddy Kennedy, Chief Financial Officer | |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin | |
Novum Securities (Broker) | Tel: +44 (0)20 7399 9400 |
Colin Rowbury | |
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com |
Paul McManus | Mob: +44(0)7980 541 893 |
About Concepta PLC (www.conceptaplc.com)
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.
myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020.
myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.